107 related articles for article (PubMed ID: 6323515)
21. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
[TBL] [Abstract][Full Text] [Related]
22. A review of clinical trials comparing HMG-CoA reductase inhibitors.
Illingworth DR; Tobert JA
Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
[TBL] [Abstract][Full Text] [Related]
23. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
[TBL] [Abstract][Full Text] [Related]
24. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
25. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.
Sartor G; Katzman P; Eizyk E; Kalén J; Nilsson A; Ugander L; Ursing D
Int J Clin Pharmacol Ther; 1995 Jan; 33(1):3-6. PubMed ID: 7711988
[TBL] [Abstract][Full Text] [Related]
26. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Branchi A; Rovellini A; Fiorenza AM; Sommariva D
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
[TBL] [Abstract][Full Text] [Related]
27. [Simvastatin in the treatment of hypercholesterolemia].
Cigala O; Pancallo MT; Della Valle M; Marasco A; Malarbi AL
Clin Ter; 1991 Jun; 137(5):333-7. PubMed ID: 1832606
[TBL] [Abstract][Full Text] [Related]
28. [Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia].
Caruzzo C; Uslenghi E; Varbella F; Caruzzo E; Marcolongo M; Brusca A
Minerva Cardioangiol; 1989 Dec; 37(12):509-15. PubMed ID: 2695857
[TBL] [Abstract][Full Text] [Related]
29. Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Kuroda M; Tsujita Y; Tanzawa K; Endo A
Lipids; 1979 Jun; 14(6):585-9. PubMed ID: 110993
[TBL] [Abstract][Full Text] [Related]
30. [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].
Wenke K; Thiery J; Meiser B; Arndtz N; Seidel D; Reichart B
Z Kardiol; 1995 Feb; 84(2):130-6. PubMed ID: 7717016
[TBL] [Abstract][Full Text] [Related]
31. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. 1976.
Endo A; Kuroda M; Tanzawa K
Atheroscler Suppl; 2004 Oct; 5(3):39-42. PubMed ID: 15531273
[No Abstract] [Full Text] [Related]
32. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation.
Castelao AM; Griñó JM; Andrés E; Gilvernet S; Serón D; Castiñeiras MJ; Roca M; Galcerán JM; González MT; Alsina J
Transplant Proc; 1993 Feb; 25(1 Pt 2):1043-6. PubMed ID: 8442035
[No Abstract] [Full Text] [Related]
33. [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Berioli S; Bentivoglio M; Conti R; Osanna RA; Savino K; Zollino L; Corea L
Cardiologia; 1990 Apr; 35(4):335-40. PubMed ID: 2245435
[TBL] [Abstract][Full Text] [Related]
34. The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.
Illingworth DR; Corbin D
Proc Natl Acad Sci U S A; 1985 Sep; 82(18):6291-4. PubMed ID: 2994068
[TBL] [Abstract][Full Text] [Related]
35. Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus. ML-236B (compactin) induces a cytochrome P-450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase.
Matsuoka T; Miyakoshi S; Tanzawa K; Nakahara K; Hosobuchi M; Serizawa N
Eur J Biochem; 1989 Oct; 184(3):707-13. PubMed ID: 2509201
[TBL] [Abstract][Full Text] [Related]
36. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals.
Endo A; Tsujita Y; Kuroda M; Tanzawa K
Biochim Biophys Acta; 1979 Nov; 575(2):266-76. PubMed ID: 508786
[TBL] [Abstract][Full Text] [Related]
37. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
Mabuchi H; Haba T; Tatami R; Miyamoto S; Sakai Y; Wakasugi T; Watanabe A; Koizumi J; Takeda R
Atheroscler Suppl; 2004 Oct; 5(3):51-5. PubMed ID: 15531275
[No Abstract] [Full Text] [Related]
38. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks.
Fears R; Richards DH; Ferres H
Atherosclerosis; 1980 Apr; 35(4):439-49. PubMed ID: 7189661
[TBL] [Abstract][Full Text] [Related]
39. Effect of ML-236B (compactin) on biliary excretion of bile salts and lipids, and on bile flow, in the rat.
Kempen HJ; De Lange J; Vos-Van Holstein MP; Van Wachem P; Havinga R; Vonk RJ
Biochim Biophys Acta; 1984 Jul; 794(3):435-43. PubMed ID: 6743675
[TBL] [Abstract][Full Text] [Related]
40. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Dobs AS; Sarma PS; Schteingart D
Metabolism; 1993 Sep; 42(9):1146-52. PubMed ID: 8412767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
